查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1239519

丛集性头痛市场：按类型、药物类别和分销渠道分类：2021-2031 年全球机遇分析和行业预测

Cluster Headache Market By Type, By Drug class, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 233 Pages | 商品交期: 2-3个工作天内

价格

丛集性头痛市场规模预计到 2021 年将达到 3.56 亿美元，到 2031 年将达到 5.2298 亿美元，2022 年至 2031 年的复合年增长率为 3.9%。

丛集性头痛是最常见的原发性头痛类型，称为三叉神经自主神经痛 (TAC)。 丛集性头痛的特征是持续 15 至 180 分钟的非常严重的单侧头痛发作，每天发作多达数次。 它的特点是疼痛的严重程度、发作的持续时间以及是否存在流泪和结膜充血等颅神经系统自主神经症状。 发作通常成群发生，一次连续发生数周至数月，随后是完全缓解期。 这种显着的疼痛与自杀倾向增加有关，尤其是在集群期。

丛集性头痛市场的驱动因素是丛集性头痛患者人数的增加以及对开发丛集性头痛有效疗法的投资增加。 此外，丛集性头痛等神经系统疾病发病率的急剧增加增加了对有效治疗头痛疾病的药物的需求，丛集性头痛发病率的增加有望推动市场增长。 例如，发表在 SAGE Journal-Cephalalgia 2022 上的一篇论文发现，挪威的丛集性头痛患病率为每 10 万人/年 48.6 例，推动了市场增长。 预计未来几年将获得监管机构批准的丛集性头痛治疗管道不断增加，预计也将推动市场扩张。

此外，政府和私人组织还为与丛集性头痛等头痛疾病相关的研发活动提供各种补助金和奖学金，这进一步推动了市场扩张。 例如，根据国际头痛学会（International Headache Society，IHS）2022 报告，IHS 支持年轻研究人员的创新和有影响力的研究，促进头痛领域年轻研究人员的职业发展，并建立头痛疾病知识库。它提供了一个“IHS Junior Research Grant”等总共 20-30 项研究补助金将增加，这些可用于头痛疾病研发的研究补助金有望推动市场增长。

然而，缓慢的药物审批和严格的监管是製约市场增长的因素。 缺乏有利的报销政策预计也将成为抑制市场增长的一个因素。

此外，对生物製剂等新型治疗药物的需求不断增加，对治疗方式的认识不断提高，以及为开发安全有效的丛集性头痛治疗剂而加大研发力度，这些都是丛集性头痛市场的主要因素。它提供了有利可图的机会对于市场。

内容

第 1 章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 主要影响因素
    • 主要投资领域
  • 波特的五力分析
    • 供应商的议价能力
    • 买家的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 中等强度的竞争
  • 市场动态
    • 促进因素
      • 丛集性头痛患病率上升
      • 开发治疗丛集性头痛的新型药物
      • 对丛集性头痛的认识不断提高
    • 抑制因素
      • 用于丛集性头痛的药物的副作用
    • 机会
      • 新兴市场的增长机会
  • 分析 COVID-19 对市场的影响

第 4 章丛集性头痛市场：按类型

  • 概览
    • 市场规模和预测
  • 反復发作
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 慢性
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 5 章丛集性头痛市场：按药物类别分类

  • 概览
    • 市场规模和预测
  • 麦角衍生物
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 钙通道阻滞剂
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 曲普坦
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 6 章丛集性头痛市场：按分销渠道

  • 概览
    • 市场规模和预测
  • 医院药房
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 药店和零售药店
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 7 章丛集性头痛市场：按地区

  • 概览
    • 市场规模和预测：按地区
  • 北美
    • 主要趋势和机会
    • 市场规模和按类型预测
    • 按药物类别划分的市场规模和预测
    • 按分销渠道划分的市场规模和预测
    • 市场规模和预测：按国家/地区分类
      • 美国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
      • 加拿大
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
      • 墨西哥
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
  • 欧洲
    • 主要趋势和机会
    • 市场规模和按类型预测
    • 按药物类别划分的市场规模和预测
    • 按分销渠道划分的市场规模和预测
    • 市场规模和预测：按国家/地区分类
      • 德国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
      • 法国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
      • 英国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
      • 意大利
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
      • 西班牙
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
      • 其他欧洲
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
  • 亚太地区
    • 主要趋势和机会
    • 市场规模和按类型预测
    • 按药物类别划分的市场规模和预测
    • 按分销渠道划分的市场规模和预测
    • 市场规模和预测：按国家/地区分类
      • 日本
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
      • 中国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
      • 印度
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
      • 澳大利亚
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
      • 韩国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
      • 其他亚太地区
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
  • 拉丁美洲/中东/非洲
    • 主要趋势和机会
    • 市场规模和按类型预测
    • 按药物类别划分的市场规模和预测
    • 按分销渠道划分的市场规模和预测
    • 市场规模和预测：按国家/地区分类
      • 巴西
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
      • 沙特阿拉伯
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
      • 南非
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测
      • 其他拉丁美洲/中东/非洲
      • 主要市场趋势、增长动力和机遇
      • 市场规模和按类型预测
      • 按药物类别划分的市场规模和预测
      • 按分销渠道划分的市场规模和预测

第 8 章竞争格局

  • 介绍
  • 关键成功策略
  • 排名前 10 位的玩家产品映射
  • 比赛仪表板
  • 竞争热图
  • 2021 年最佳球员排名

第 9 章公司简介

  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • FRESENIUS SE & Co. KGaA（Fresenius Kabi）
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Arrotex Australia Group
  • Grunenthal
Product Code: A14443

The cluster headache market size valued for $356.00 million in 2021 and is estimated to reach $522.98 million by 2031, exhibiting a CAGR of 3.9% from 2022 to 2031.  

Cluster headache is the most common type of the primary headache known as trigeminal autonomic cephalgia (TACs). Cluster headache is characterized by attacks of very severe, unilateral headache lasting 15-180 minutes, up to several times per day. It is distinguished by the severe nature of the pain, length of attacks, and presence of cranial autonomic symptoms such as lacrimation and conjunctival injection. Attacks often cluster and can occur in series for weeks or months at a time, followed by a period of complete remission. This significant pain is accompanied by increased suicidality during cluster periods, particularly during the time of the headache.   

The driving factors for cluster headache market are increase in number of patients suffering from cluster headache, and rise in investments for development of effective medications for cluster headache.  Moreover, surge in incidences of neurological disorders such as cluster headache results in demand of effective medications for treating headache disorders, thus increasing incidences of cluster headache is expected to drive the growth of the market. For instance, according to article published in SAGE Journal - Cephalalgia 2022, stated that, prevalence of cluster headache in Norway was found to be 48.6 per 100,000/year, thereby driving the growth of the market. In addition, increase in number of pipeline medications for treating cluster headache that is anticipated to receive regulatory approval in the upcoming years is projected to propel market expansion.     

Further, various grants and fellowships are provided by government and private institutions for research and development activities involving headache disorders such as cluster headache, which further propels the market expansion. For instance, according to report of International Headache Society (IHS) 2022, stated that, IHS offers total 20-30 fellowships such as 'IHS Junior Research Grant' to support innovative and impactful research from young investigators, promote the career of young investigators in the field of headache and increase the knowledge base of headache disorders, thus such available fellowships for R&D in headache disorders is anticipated to drive the growth of the market.    

However, lengthy drug approval process and strict regulatory pathways are the factors that restrain the growth of the market. In addition, absence of favorable reimbursement policies is also expected to constrain the growth of the market.   

Further, rise in demand for novel therapies such as biologics, increase in awareness about treatment options and increase in R&D to develop safe and efficacious drugs for cluster headache treatment offer lucrative opportunities to key players of the cluster headache market.  

The cluster headache market is segmented into type, drug class, distribution channel and region. By type, the market is categorized into episodic and chronic. By drug class, the market is categorized into ergot derivatives, calcium channel blockers, triptans, and others. By distribution channel, the market is categorized into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).  

Major Key players that operate in the global cluster headache market are Arrotex Australia Group, AstraZeneca, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.  

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cluster headache market analysis from 2021 to 2031 to identify the prevailing cluster headache market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the cluster headache market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global cluster headache market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug class

  • Ergot derivatives
  • Calcium channel blockers
  • Triptans
  • Others

By Distribution channel

  • Hospital pharmacies
  • Drug stores and retail pharmacies
  • Others

By Type

  • Episodic
  • Chronic

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • Dr. Reddy's Laboratories Ltd.
  • FRESENIUS SE & Co. KGaA (Fresenius Kabi)
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Arrotex Australia Group
  • Grunenthal
  • Eli Lilly and Company
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate bargaining power of buyers
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate threat of new entrants
    • 3.3.5. Moderate intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of cluster headache
      • 3.4.1.2. Development of novel therapeutics for treatment of cluster headache
      • 3.4.1.3. Increase in awareness about cluster headache
    • 3.4.2. Restraints
      • 3.4.2.1. Side effects associated with medications used for cluster headache
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: CLUSTER HEADACHE MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Episodic
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Chronic
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: CLUSTER HEADACHE MARKET, BY DRUG CLASS

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Ergot derivatives
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Calcium channel blockers
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Triptans
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug stores and retail pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: CLUSTER HEADACHE MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Drug class
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Type
      • 7.2.5.1.3. Market size and forecast, by Drug class
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Type
      • 7.2.5.2.3. Market size and forecast, by Drug class
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Type
      • 7.2.5.3.3. Market size and forecast, by Drug class
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Drug class
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Type
      • 7.3.5.1.3. Market size and forecast, by Drug class
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Type
      • 7.3.5.2.3. Market size and forecast, by Drug class
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Type
      • 7.3.5.3.3. Market size and forecast, by Drug class
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Type
      • 7.3.5.4.3. Market size and forecast, by Drug class
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Type
      • 7.3.5.5.3. Market size and forecast, by Drug class
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Type
      • 7.3.5.6.3. Market size and forecast, by Drug class
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Drug class
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Type
      • 7.4.5.1.3. Market size and forecast, by Drug class
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Type
      • 7.4.5.2.3. Market size and forecast, by Drug class
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Type
      • 7.4.5.3.3. Market size and forecast, by Drug class
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Type
      • 7.4.5.4.3. Market size and forecast, by Drug class
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Type
      • 7.4.5.5.3. Market size and forecast, by Drug class
      • 7.4.5.5.4. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Type
      • 7.4.5.6.3. Market size and forecast, by Drug class
      • 7.4.5.6.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Drug class
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Type
      • 7.5.5.1.3. Market size and forecast, by Drug class
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Type
      • 7.5.5.2.3. Market size and forecast, by Drug class
      • 7.5.5.2.4. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Type
      • 7.5.5.3.3. Market size and forecast, by Drug class
      • 7.5.5.3.4. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Type
      • 7.5.5.4.3. Market size and forecast, by Drug class
      • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Dr. Reddy's Laboratories Ltd.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Eli Lilly and Company
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. FRESENIUS SE & Co. KGaA (Fresenius Kabi)
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. GlaxoSmithKline plc
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Novartis AG
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Pfizer Inc.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Sun Pharmaceutical Industries Ltd.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Teva Pharmaceutical Industries Ltd.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Arrotex Australia Group
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Key strategic moves and developments
  • 9.10. Grunenthal
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. CLUSTER HEADACHE MARKET FOR EPISODIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. CLUSTER HEADACHE MARKET FOR CHRONIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. GLOBAL CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. CLUSTER HEADACHE MARKET FOR ERGOT DERIVATIVES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. CLUSTER HEADACHE MARKET FOR CALCIUM CHANNEL BLOCKERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. CLUSTER HEADACHE MARKET FOR TRIPTANS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. CLUSTER HEADACHE MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. GLOBAL CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. CLUSTER HEADACHE MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. CLUSTER HEADACHE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. CLUSTER HEADACHE MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. CLUSTER HEADACHE MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. NORTH AMERICA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. NORTH AMERICA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. NORTH AMERICA CLUSTER HEADACHE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. U.S. CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. U.S. CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. U.S. CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. CANADA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. CANADA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. CANADA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. MEXICO CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. MEXICO CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. MEXICO CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. EUROPE CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. EUROPE CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. EUROPE CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. EUROPE CLUSTER HEADACHE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. GERMANY CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. GERMANY CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. GERMANY CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. FRANCE CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. FRANCE CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. FRANCE CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. UK CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. UK CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. UK CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. ITALY CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. ITALY CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. ITALY CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. SPAIN CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. SPAIN CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. SPAIN CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. REST OF EUROPE CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. REST OF EUROPE CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. REST OF EUROPE CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. JAPAN CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. JAPAN CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. JAPAN CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. CHINA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. CHINA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. CHINA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. INDIA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. INDIA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. INDIA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. AUSTRALIA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. AUSTRALIA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. AUSTRALIA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. SOUTH KOREA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. SOUTH KOREA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. SOUTH KOREA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. LAMEA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. LAMEA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. LAMEA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. LAMEA CLUSTER HEADACHE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. BRAZIL CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. BRAZIL CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. BRAZIL CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. SAUDI ARABIA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. SAUDI ARABIA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. SAUDI ARABIA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. SOUTH AFRICA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. SOUTH AFRICA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SOUTH AFRICA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. REST OF LAMEA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. REST OF LAMEA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. REST OF LAMEA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. DR. REDDY'S LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 88. DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 89. DR. REDDY'S LABORATORIES LTD.: PRODUCT SEGMENTS
  • TABLE 90. DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 91. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 92. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 93. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
  • TABLE 94. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 95. ELI LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 96. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): KEY EXECUTIVES
  • TABLE 97. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): COMPANY SNAPSHOT
  • TABLE 98. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): PRODUCT SEGMENTS
  • TABLE 99. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): PRODUCT PORTFOLIO
  • TABLE 100. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 101. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 102. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 103. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 104. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 105. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 106. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 107. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 108. PFIZER INC.: KEY EXECUTIVES
  • TABLE 109. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 110. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 111. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 114. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 115. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 117. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 118. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 120. ARROTEX AUSTRALIA GROUP: KEY EXECUTIVES
  • TABLE 121. ARROTEX AUSTRALIA GROUP: COMPANY SNAPSHOT
  • TABLE 122. ARROTEX AUSTRALIA GROUP: PRODUCT SEGMENTS
  • TABLE 123. ARROTEX AUSTRALIA GROUP: PRODUCT PORTFOLIO
  • TABLE 124. ARROTEX AUSTRALIA GROUP: KEY STRATERGIES
  • TABLE 125. GRUNENTHAL: KEY EXECUTIVES
  • TABLE 126. GRUNENTHAL: COMPANY SNAPSHOT
  • TABLE 127. GRUNENTHAL: PRODUCT SEGMENTS
  • TABLE 128. GRUNENTHAL: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. CLUSTER HEADACHE MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF CLUSTER HEADACHE MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN CLUSTER HEADACHE MARKET (2022-2031)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCLUSTER HEADACHE MARKET
  • FIGURE 10. CLUSTER HEADACHE MARKET, BY TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR EPISODIC, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR CHRONIC, BY COUNTRY 2021-2031(%)
  • FIGURE 13. CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR ERGOT DERIVATIVES, BY COUNTRY 2021-2031(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR CALCIUM CHANNEL BLOCKERS, BY COUNTRY 2021-2031(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR TRIPTANS, BY COUNTRY 2021-2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 18. CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 22. CLUSTER HEADACHE MARKET BY REGION, 2021
  • FIGURE 23. U.S. CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. CANADA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. MEXICO CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. GERMANY CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. FRANCE CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. UK CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. ITALY CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. SPAIN CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. REST OF EUROPE CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. JAPAN CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. CHINA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. INDIA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. AUSTRALIA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. SOUTH KOREA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. BRAZIL CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. SAUDI ARABIA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SOUTH AFRICA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. REST OF LAMEA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: CLUSTER HEADACHE MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2021
  • FIGURE 49. DR. REDDY'S LABORATORIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 50. DR. REDDY'S LABORATORIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 51. DR. REDDY'S LABORATORIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 52. ELI LILLY AND COMPANY: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 53. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 54. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 55. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 56. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 57. GLAXOSMITHKLINE PLC: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 58. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 59. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 60. NOVARTIS AG: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 61. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 62. NOVARTIS AG: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 63. PFIZER INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 64. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 65. PFIZER INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 66. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 67. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 68. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 69. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 70. GRUNENTHAL: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 71. GRUNENTHAL: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 72. GRUNENTHAL: REVENUE SHARE BY REGION, 2021 (%)